DexCom, Inc. $DXCM Shares Acquired by Mitsubishi UFJ Trust & Banking Corp

Mitsubishi UFJ Trust & Banking Corp grew its position in shares of DexCom, Inc. (NASDAQ:DXCM) by 7.5% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 597,536 shares of the medical device company’s stock after purchasing an additional 41,643 shares during the quarter. Mitsubishi UFJ Trust & Banking Corp owned approximately 0.15% of DexCom worth $52,159,000 as of its most recent SEC filing.

Other hedge funds have also recently added to or reduced their stakes in the company. SWS Partners acquired a new position in DexCom in the 2nd quarter worth about $1,661,000. Baader Bank Aktiengesellschaft purchased a new stake in shares of DexCom in the second quarter valued at approximately $393,000. Jennison Associates LLC raised its stake in shares of DexCom by 9.4% during the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock worth $1,005,367,000 after buying an additional 994,300 shares during the period. Assenagon Asset Management S.A. lifted its position in shares of DexCom by 85.7% during the 2nd quarter. Assenagon Asset Management S.A. now owns 1,208,255 shares of the medical device company’s stock valued at $105,469,000 after buying an additional 557,576 shares in the last quarter. Finally, Mn Services Vermogensbeheer B.V. grew its stake in DexCom by 4.9% in the 2nd quarter. Mn Services Vermogensbeheer B.V. now owns 146,600 shares of the medical device company’s stock valued at $12,797,000 after acquiring an additional 6,800 shares during the period. 97.75% of the stock is owned by hedge funds and other institutional investors.

Insider Activity at DexCom

In other DexCom news, Director Richard Alexander Collins sold 3,948 shares of the company’s stock in a transaction dated Monday, November 10th. The shares were sold at an average price of $55.17, for a total value of $217,811.16. Following the transaction, the director owned 37,994 shares of the company’s stock, valued at $2,096,128.98. This represents a 9.41% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this link. Also, COO Jacob Steven Leach purchased 18,200 shares of the company’s stock in a transaction on Monday, November 10th. The shares were bought at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the completion of the transaction, the chief operating officer owned 331,697 shares of the company’s stock, valued at approximately $18,256,602.88. The trade was a 5.81% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing. Insiders have sold 10,343 shares of company stock valued at $710,852 over the last 90 days. Corporate insiders own 0.32% of the company’s stock.

DexCom Trading Up 2.5%

Shares of DexCom stock opened at $59.61 on Thursday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.52 and a quick ratio of 1.35. The stock’s 50 day simple moving average is $68.12 and its 200-day simple moving average is $77.39. The stock has a market cap of $23.25 billion, a P/E ratio of 41.40, a P/E/G ratio of 1.43 and a beta of 1.40. DexCom, Inc. has a 1-year low of $54.11 and a 1-year high of $93.25.

DexCom (NASDAQ:DXCM) last released its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, topping analysts’ consensus estimates of $0.57 by $0.04. DexCom had a return on equity of 30.41% and a net margin of 13.29%.The company had revenue of $1.21 billion for the quarter, compared to analyst estimates of $1.18 billion. During the same quarter in the previous year, the company posted $0.45 earnings per share. The firm’s revenue for the quarter was up 21.6% compared to the same quarter last year. DexCom has set its FY 2025 guidance at EPS. Analysts predict that DexCom, Inc. will post 2.03 EPS for the current fiscal year.

Analyst Ratings Changes

DXCM has been the topic of several recent analyst reports. JPMorgan Chase & Co. decreased their price objective on shares of DexCom from $90.00 to $75.00 and set a “neutral” rating on the stock in a report on Friday, October 31st. Royal Bank Of Canada decreased their price target on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating on the stock in a research note on Friday, October 31st. William Blair upgraded DexCom to a “strong-buy” rating in a research note on Thursday, July 31st. Oppenheimer downgraded DexCom from an “outperform” rating to a “market perform” rating in a research report on Monday, September 8th. Finally, TD Cowen dropped their price target on DexCom from $100.00 to $84.00 and set a “buy” rating for the company in a research report on Friday, October 31st. Three equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $87.62.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.